SignatureFD’s Heron Therapeutics HRTX Stock Holding History

SignatureFD’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-353	Closed	-$2K	–	3216
2022 Q1	$2K	Buy	+353	New	+$2.58K	﹤0.01%	2808
2021 Q4	–	Sell	-6,028	Closed	-$64K	–	3173
2021 Q3	$64K	Hold	6,028	–	–	﹤0.01%	1179
2021 Q2	$94K	Buy	6,028 +1,653	+38%	+$26.3K	﹤0.01%	976
2021 Q1	$71K	Buy	4,375 +1,125	+35%	+$20.1K	﹤0.01%	1015
2020 Q4	$69K	Buy	3,250 +2,000	+160%	+$34.8K	﹤0.01%	933
2020 Q3	$19K	Buy	+1,250	New	+$19.5K	﹤0.01%	1399

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

SignatureFD's HRTX Position: Q2 2022 in Review

SignatureFD sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 353 shares — an estimated $2K sold.

SignatureFD first reported a position in HRTX in Q3 2020 and held it in 6 quarters. The position peaked at $94K in Q2 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

SignatureFD reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
SignatureFD sold 353 Heron Therapeutics shares in Q2 2022, an estimated $2K.
SignatureFD first reported a position in Heron Therapeutics in Q3 2020 and held it in 6 quarters.
SignatureFD's Heron Therapeutics position peaked at $94K in Q2 2021.
174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on SignatureFD's 13F filing for Q2 2022, filed 10 Aug 2022.